Launched in 2004, this grant program (previously called the Program Project Development grant) provides funds for large ovarian cancer research projects that involve several investigators within one institution or collaborations between groups in multiple institutions. The grant is for investigators seeking to develop program project grant applications for submission to peer-review funding agencies (e.g. NCI, RO1, SPORE, DOD). Support of $300,000 annually for three years will be awarded to the institution(s) in which the recipients will conduct the research.
Launched in December 2000, the Liz Tilberis Early Career Award (formerly called the Liz Tilberis Scholars Award) is for junior faculty with a strong commitment to an investigative career in ovarian cancer research. These awards support a substantial time commitment to research and academic endeavors in ovarian cancer. Each grantee will receive a three-year grant of $150,000 per year. The program honors OCRF’s late president, Liz Tilberis.
The Ann and Sol Schreiber Mentored Investigator Award (formerly the Ann Schreiber Research Training Programs of Excellence Award) provides funding for trainees who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research. Applicants must be clinical fellows (Gynecologic Oncology, Medical Oncology), or post-doctoral fellows. Candidates for this program must have an MD or a PhD degree. The award provides a total of $75,000 to be used over one or two years, and will encourage the recipient’s research career in the field of ovarian cancer. This grant is named in honor of Ann and Sol Schreiber, OCRFA's founders.
Although OCRFA no longer offers this type of grant, from 1998 – 2007, OCRF offered grants though the Individual Investigator Awards Program to advance outstanding researchers early in their careers whose projects focus on early detection, screening, and basic translational research. These innovative two year grants, funded at $100,000, were intended to yield results within two years or less. The ultimate aim of the program was to enable investigators, with promising results in hand, to obtain grants from the National Cancer Institute or other large funding agencies.